Medicilon is delighted to announce that Dr. Xiaodong (Mark) Zhang has joined us to further develop the growing Preclinical Research accounts. Dr. Zhang comes with a wealth of experience within this field.
Picture of Dr.zhang
Dr. Zhang was the VP of Preclinical Research, Deputy Director of Department of Health Toxicology, SMMU; Deputy Director of Center for Evaluation of Drug Safety, SMMU; Drug Reviewer of Center for Drug Evaluation , CFDA and expert for Drug Consulting, Center for Drug Evaluation , CFDA.
Just as Dr. Chunlin Chen, CEO of Medicilon, said, “I’m confident that Mark will play a key role in providing and implementing high quality solutions for our clients.”